Dr. Wyatt McDonnell

Dr. Wyatt McDonnell is Co-Founder, CEO, and Chairman of the Board of Directors at Infinimmune, a biotechnology company utilizing natural immunity to transform natural antibodies into safer and more effective drugs for complex diseases. Previously, Wyatt worked on world-class single cell technologies at 10x Genomics where he was Technical Lead and Developer of Barcode-Enabled Antigen Mapping (BEAM). Wyatt also developed 10x Genomics’ first therapeutic antibodies and core immunology intellectual property behind three commercial products to interrogate the immune repertoire. He has co-authored 31 peer-reviewed papers in journals including Nature, Cell, and Nature Medicine, and 19 published patents in relation to immunobiology, genomics, and disease. He has been invited to speak at conferences including PEGS, the Keystone Symposia, the World Vaccine Congress, and PMWC. He received his Ph.D. and M.Sc in Microbiology and Immunology from the University of Vanderbilt School of Medicine and B.Sc in Molecular Biology at Hillsdale College.